His laboratory research focused on the role of neuron-glial interactions in the central nervous system. and Actio Biosciences have collectively raised over 120 million in venture capital funding from blue. Barres was a Fellow of the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. The three companies that have signed on to StudioLabs Protego Biopharma, Velia, Inc. He was a founding member of the Myelin Repair Foundation that focuses on translational research to develop new drugs for multiple sclerosis. Barres won many teaching awards at Stanford and was the creator and director of the Masters of Science in Medicine Program, a program at Stanford University designed to train PhD students in human biology and disease. Barres completed his internship and residency in neurology at the Cornell Cooperating Hospitals Program and his postdoctoral fellowship with Martin Raff at University College London. founder and CEO of Actio Biosciences, a venture-backed company focused on using bioinformatics to systematically interrogate the genome to identify novel. Although generalist, the Biosciences program gives a certain specialization through the choice of optional Electives (UE) and internships in laboratories (18 weeks in M1 and 20 weeks in M2). He received his BS from Massachusetts Institute of Technology, his MD from Dartmouth Medical School and his PhD at Harvard Medical School in the laboratory of David Corey. Barres co-founded Annexon Biosciences and was a Professor and Chair of Neurobiology at Stanford University School of Medicine. CO-FOUNDER, ANNEXON, FORMER CHAIR OF NEUROBIOLOGY, STANFORD UNIVERSITYĭr. Company Number 6099130 Incorporation Date 20 July 2021 (6 months ago) Company Type Domestic Corporation Jurisdiction Delaware (US) Registered.